Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs
The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options.
Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
